Perhaps no other recent area of investing has generated as much debate as stem-cell research, where potential for profits comes with such profound controversy over when human life begins and when it should be protected.
The Investor Responsibility Research Center, Washington, hopes to provide some clarity with a new stem-cell research analysis report for investors. It provides an impartial analysis covering the recent political, social and financial developments affecting the industry.
The study includes 25 of some 40 publicly traded companies identified as being involved in stem-cell research, including Amgen Inc., Geron Corp., Eli Lilly & Co., Sanofi-Aventis and Johnson & Johnson Inc.
"With stem-cell research inextricably linked to the controversies surrounding abortion and cloning, many institutional investors are struggling to develop a policy regarding investments in this fast-paced field," Craig Metrick, IRRC director-corporate benchmarking service, said in a statement. "Portfolio managers who need information on this issue can obtain historical and the most current data available in this report."
The 78-page report is available for $100 from the IRRC.